News & Updates

Use of RAS inhibitors associated with lower cancer risk in T2D
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022 byNatalia Reoutova

A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.

Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Alcohol consumption ups risk of CVD, all-cause mortality in men
Alcohol consumption ups risk of CVD, all-cause mortality in men
01 Oct 2022
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022

Among patients with type 2 acute myocardial infarction (AMI), the absence of standard modifiable cardiovascular risk factors (SMuRF) appears to worsen poor outcomes, such as mortality, stroke, and major adverse cardiovascular and cerebrovascular events (MACCE), a new study has found.

Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022